Abstract
Adenocarcinomas of the gastroesophageal junction (GEJ) require multimodal treatment approaches to accomplish good local control and overall survival. While early T1/2 N0 tumors are treated with surgery alone, they are only found in a small subset of patients due to the lack of symptoms at this stage. Most of the tumors are detected in locally advanced stage where surgery alone results in disappointing outcome. Chemotherapy and/or chemoirradiation in the neoadjuvant setting are used to improve conditions for oncological surgery. They aim to achieve a downsizing with a pathological complete remission in the optimal case, improve R0 rates, and upfront treat microscopic metastatic tumor cells. The optimal neoadjuvant treatment approach—chemotherapy, chemoirradiation, or a multiphase approach of both—is yet unclear. Chemoirradiation can improve local control after incomplete surgery and is an important option for patients unfit for surgery. In addition, it enables symptom relief in a palliative setting, namely dysphagia, pain, or bleeding. While target volumes are very much standardized, new technologies as image-guided intensity-modulated radiotherapy (IG-IMRT) and particle therapy have the potential to improve the therapeutic window by minimizing toxicity. Challenges of the present and the future will be the combination of radiotherapy with other cytostatic drugs and modern targeted therapies. This should ideally be integrated into a multimodal setting that is able to identify risk groups according to predictive markers and tumor response, altogether leading to a personalized oncological approach.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ajani JA, Komaki R, Putnam JB et al (2001) A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 92:279–286
Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R (2011) Guidelines for the management of oesophageal and gastric cancer. Gut 60:1449–1472
Aoyagi T, Shuto K, Okazumi S, Shimada H, Kazama T, Matsubara H (2011) Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer. Dig Surg 28:252–257
Bain GH, Petty RD (2010) Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist 15:270–284
Blank S, Blaker H, Schaible A et al (2012) Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbecks Arch Surg 397:45–55
Burmeister BH, Thomas JM, Burmeister EA et al (2011) Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 47:354–360
Bystricky B, Okines AF, Cunningham D (2011) Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 71:541–555
Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Fakhrian K, Gamisch N, Schuster T, Thamm R, Molls M, Geinitz H (2012) Salvage radiotherapy in patients with recurrent esophageal carcinoma. Strahlenther Onkol 188:136–142
Fiorica F, Di Bona D, Schepis F et al (2004) Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 53:925–930
Fujitani K, Ajani JA, Crane CH et al (2007) Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol 14:2010–2017
Greer SE, Goodney PP, Sutton JE, Birkmeyer JD (2005) Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137:172–177
Ilson DH, Minsky BD, Ku GY et al. (2011) Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer
Jamil LH, Gill KR, Wallace MB (2008) Staging and restaging of advanced esophageal cancer. Curr Opin Gastroenterol 24:530–534
Jensen AD, Grehn C, Nikoghosyan A et al (2009) Catch me if you can—the use of image guidance in the radiotherapy of an unusual case of esophageal cancer. Strahlenther Onkol 185:469–473
Kranzfelder M, Schuster T, Geinitz H, Friess H, Buchler P (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768–783
Leibl BJ, Vitz S, Schafer W, Alfrink M, Gschwendtner A, Grabenbauer GG (2011) Adenocarcinoma of the esophagogastric junction: neoadjuvant radiochemotherapy and radical surgery: early results and toxicity. Strahlenther Onkol 187:231–237
Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the Municon phase II trial. Lancet Oncol 8:797–805
Lordick F, Ott K, Krause BJ (2010) New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol 21(Suppl 7):294–299
Lordick F, Ott K, Krause BJ (2011a) Positron emission tomography—current role in the diagnosis and treatment of upper gastrointestinal carcinomas. Dtsch Med Wochenschr 136:1061–1066
Lordick F, Ott K, Sendler A (2011b) Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy. Chirurg 82:968–973
Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD (2009) Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol 15:4962–4968
Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730
Matzinger O, Gerber E, Bernstein Z et al (2009) EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. Radiother Oncol 92:164–175
Muijs CT, Beukema JC, Mul VE, Plukker JT, Sijtsema NM, Langendijk JA (2012) External beam radiotherapy combined with intraluminal brachytherapy in esophageal carcinoma. Radiother Oncol 102:303–308
Okines AF, Cunningham D (2010) Multimodality treatment for localized gastro-oesophageal cancer. Ann Oncol 21 Suppl 7:vii286–vii293
Power DG, Ilson DH (2009) Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Ther Adv Med Oncol 1:145–165
Ruhstaller T, Pless M, Dietrich D et al (2011) Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 29:626–631
Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692
Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–856
Strauss J, Hershman DL, Buono D et al (2010) Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys 76:1404–1412
Sun YS, Cui Y, Tang L et al (2011) Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient. AJR Am J Roentgenol 197:W23–W29
van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Welsh J, Gomez D, Palmer MB et al (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81:1336–1342
Welsh J, Palmer MB, Ajani JA et al (2012) Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82:468–474
Wieder HA, Brucher BL, Zimmermann F et al (2004) Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 22:900–908
Xing L, Thorndyke B, Schreibmann E et al (2006) Overview of image-guided radiation therapy. Med Dosim 31:91–112
Ychou M, Boige V, Pignon JP et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721
Yoon HH, Shi Q, Sukov WR et al (2012) Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 18:546–554
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Sterzing, F., Grenacher, L., Debus, J. (2012). Radiotherapy of Gastroesophageal Junction Cancer. In: Otto, F., Lutz, M. (eds) Early Gastrointestinal Cancers. Recent Results in Cancer Research, vol 196. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31629-6_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-31629-6_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-31628-9
Online ISBN: 978-3-642-31629-6
eBook Packages: MedicineMedicine (R0)